T. Rowe Price Associates
TMCI icon

T. Rowe Price Associates’s Treace Medical Concepts TMCI Stock Holding History

T. Rowe Price Associates’s Portfolio TMCI Stock Details TMCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35K Hold
25,627
– – ﹤0.01% 3090
2025
Q4 		$63K Hold
25,627
– – ﹤0.01% 3012
2025
Q3 		$172K Buy
25,627
+3,510
+16% +$22.9K ﹤0.01% 2825
2025
Q2 		$131K Buy
22,117
+1,118
+5% +$7.28K ﹤0.01% 2838
2025
Q1 		$177K Buy
20,999
+1,943
+10% +$17.5K ﹤0.01% 2691
2024
Q4 		$142K Buy
19,056
+3,452
+22% +$23.1K ﹤0.01% 2779
2024
Q3 		$91K Hold
15,604
– – ﹤0.01% 2838
2024
Q2 		$104K Buy
15,604
+2,632
+20% +$21.3K ﹤0.01% 2755
2024
Q1 		$170K Buy
12,972
+1,385
+12% +$18.5K ﹤0.01% 2667
2023
Q4 		$148K Buy
11,587
+1,107
+11% +$11.2K ﹤0.01% 2634
2023
Q3 		$138K Buy
10,480
+1,323
+14% +$24.2K ﹤0.01% 2596
2023
Q2 		$235K Buy
+9,157
New +$236K ﹤0.01% 2469

Other funds holding TMCI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CBU
CIBC Bancorp USA Chicago, Illinois $74.4B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates's TMCI Position: Q1 2026 in Review

T. Rowe Price Associates held its Treace Medical Concepts (TMCI) position steady in Q1 2026 at 25,627 shares worth $35K. The position accounts for ﹤0.01% of the portfolio, ranked #3090.

T. Rowe Price Associates first reported a position in TMCI in Q2 2023 and has held it in 12 quarters since. The position peaked at $235K in Q2 2023. 118 funds tracked by Wall St. Rank hold TMCI as of Q1 2026.

  • T. Rowe Price Associates held 25,627 shares of Treace Medical Concepts worth $35K as of Q1 2026.
  • T. Rowe Price Associates left its Treace Medical Concepts share count unchanged in Q1 2026.
  • Treace Medical Concepts made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #3090 holding.
  • T. Rowe Price Associates first reported a position in Treace Medical Concepts in Q2 2023 and has held it in 12 quarters since.
  • T. Rowe Price Associates's Treace Medical Concepts position peaked at $235K in Q2 2023.
  • 118 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.